Thymosin Beta-4 Restores Blood Flow in Critically Ischemic Limbs by Growing New Blood Vessels | Research

The takeaway

Thymosin β4 promoted angiogenesis in critical limb ischemia mice by activating the Notch/NF-κB pathway, boosting VEGF, angiopoietin-2, and blood vessel formation.

Reversed pathway blockade
Tβ4 overcame both Notch and NF-κB inhibition to restore angiogenesis, confirming pathway-specific mechanism

What the researchers found

Tβ4 promoted angiogenesis in CLI mice by upregulating VEGFA, Ang2, tie2, CD31, and α-SMA via Notch/NF-κB pathway activation, and reversed the effects of pathway inhibitors.

Why it matters

CLI affects millions and often leads to amputation. Tβ4's ability to grow new blood vessels through well-defined pathways makes it a strong candidate for limb salvage therapy.

The numbers in context

Upregulated Ang2, tie2, VEGFA, CD31, alpha-SMA, N1ICD, Notch3, NF-kB, p-p65; reversed DAPT and BMS effects

How the study worked

Lentiviral Tβ4 overexpression in HUVECs and CLI mouse model; Notch inhibitor (DAPT) and NF-κB inhibitor (BMS) used for pathway confirmation; cell viability, tube formation, wound healing, Western blot, qPCR, immunofluorescence, immunohistochemistry.

Who was studied

Critical limb ischemia mouse model; HUVECs (human umbilical vein endothelial cells)

What this study cannot tell us

Mouse CLI model — surgical ischemia may not fully replicate chronic human peripheral artery disease; lentiviral overexpression differs from peptide administration; group sizes not specified.

How to read the evidence

Moderate — comprehensive in vitro and in vivo mechanistic study with pathway confirmation, but lentiviral delivery and unspecified group sizes.

When this study was published

Published in 2020; Tβ4 for cardiovascular indications continues in preclinical development.

The bigger picture

Therapeutic angiogenesis is a major goal for peripheral artery disease. Tβ4 has already shown wound healing and cardiac repair properties — CLI adds another compelling indication.

Questions still open

Would injectable Tβ4 protein (rather than gene therapy) achieve the same effects in CLI?
How does Tβ4-driven angiogenesis compare to VEGF gene therapy trials for CLI?
Could Tβ4 be combined with revascularization surgery for better outcomes?

Common questions

What is critical limb ischemia?

The most severe form of peripheral artery disease where blood flow is so restricted that tissue death and gangrene occur, often requiring amputation if untreated.

How does thymosin β4 grow blood vessels?

It activates the Notch/NF-κB signaling pathway in blood vessel cells, which turns on VEGF and other growth factors that stimulate new blood vessel formation (angiogenesis).

Read the original research

Thymosin‑β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF‑κB pathway.

International journal of molecular medicine, 46(4), 1347-1358

View on PubMed ↗Publisher’s paper ↗

Citation

Lv, Shumin; Cai, Hongwen; Xu, Yifei; Dai, Jin; Rong, Xiqing; Zheng, Lanzhi. (2020). Thymosin‑β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF‑κB pathway.. International journal of molecular medicine, 46(4), 1347-1358. https://doi.org/10.3892/ijmm.2020.4701